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ABSTRACT
Introduction Evidence indicates that people with the 
common inflammatory skin diseases atopic eczema or 
psoriasis are at increased risk of mental illness. However, 
the reasons for the relationship between skin disease and 
common mental disorders (ie, depression and anxiety) or 
severe mental illnesses (ie, schizophrenia, bipolar disorder 
and other psychoses) are unclear. Therefore, we aim 
to synthesise the available evidence regarding the risk 
factors for mental illness in adults with atopic eczema or 
psoriasis.
Methods and analysis We will conduct a systematic 
review of randomised controlled trials, cohort, case–
control and cross- sectional studies. We will search the 
following databases from inception to March 2020: 
Medline, Embase, Global Health, Scopus, the Cochrane 
Library, Web of Science, Base, PsycInfo, the Global 
Resource of Eczema Trials, and the grey literature 
databases Open Grey, PsycExtra and the New York 
Academy of Medicine Grey Literature Report. We will also 
search the bibliographies of eligible studies and relevant 
systematic reviews to identify additional relevant studies. 
Citation searching of large summary papers will be used 
to further identify relevant publications. Two reviewers 
will initially review study titles and abstracts for eligibility, 
followed by full text screening. We will extract data using a 
standardised data extraction form. We will assess the risk 
of bias of included studies using the Quality in Prognosis 
Studies tool. We will synthesise data narratively, and if 
studies are sufficiently homogenous, we will consider a 
meta- analysis. We will assess the quality of the evidence 
using the Grading of Recommendations, Assessment, 
Development and Evaluation framework.
Ethics and dissemination Ethical approval is not 
required for a systematic review. Results of the review will 
be published in a peer- reviewed journal and disseminated 
through conferences.
PROSPERO registration number CRD42020163941.
INTRODUCTION
Psoriasis and atopic eczema are inflammatory 
skin conditions associated with considerable 
morbidity and reduced quality of life for both 
sufferers and their families. Atopic eczema 
and psoriasis are common in the UK popu-
lation—psoriasis affects between 1.3% and 
2.6% of adults,1 and the prevalence of atopic 
eczema in adults is approximately 2.5%.2 Simi-
larly, mental illness is common. According 
to the 2017 Global Burden of Disease Study, 
mental illness is one of the leading causes 
of years lived with disability worldwide.3 In 
England, 17% of adults have common mental 
disorders (CMD- including depression or 
anxiety).4 Severe mental illness (SMI—
including schizophrenia, bipolar affective 
disorder and other psychoses) affects nearly 
1% of the UK population.4 Individuals with 
SMI experience substantial health inequal-
ities; they are at increased risk of serious 
health problems (eg, diabetes mellitus and 
cardiovascular disease) and die up to 20 years 
earlier than the general population.4 5
Associations between atopic eczema or 
psoriasis and mental illness are well estab-
lished. Evidence suggests that people with 
atopic eczema or psoriasis are at increased risk 
of mental illness.6–14 The temporal sequence 
of the associations between skin disease and 
mental illness is also well recognised, with 
evidence suggesting that atopic eczema or 
Strengths and limitations of this study
 ► This protocol promotes transparent review methods, 
enables comparison of our final review to our ini-
tial plans, minimises risk of bias, and reduces the 
chance of unplanned duplication.
 ► Our systematic review will be the first to critically 
evaluate studies of the risk factors for mental illness 
in adults with atopic eczema or psoriasis.
 ► We will ensure our review is comprehensive by 
searching multiple scientific literature databases 
(including specific grey literature databases), in-
cluding a range of study types and not limiting to 
English- language studies.
 ► However, the studies we include may use heteroge-
nous methods and be of variable quality, which may 
limit our ability to calculate pooled estimates from 
meta- analysis and may limit our conclusions.
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psoriasis precedes mental illness diagnosis.10 12 However, 
the reasons for the relationship between inflammatory 
skin disease and mental illness are unclear. To the best of 
our knowledge, there are no existing systematic reviews 
addressing risk factors for the relationship between 
atopic eczema or psoriasis and mental illness in adults. 
Previous systematic reviews have aimed to establish 
summary measure of effects for the association between 
either atopic eczema or psoriasis and specific mental 
illnesses (eg, depression); the majority have focused on 
the relationship between atopic eczema or psoriasis and 
CMDs.15–19 One systematic review has investigated the 
risk factors that mediate the association between atopic 
eczema and mental illness in children and adolescents 
only. The majority of studies in this review of children 
were conducted in European countries or territories. 
Meta- analysis of the 35 studies included in the review 
found that although demographic factors such as age, sex 
and socioeconomic status did not moderate the risk of 
developing mental illness in children with atopic eczema, 
children from predominantly minority ethnic back-
grounds were more likely to be diagnosed with a mental 
illness in comparison with their Caucasian counterparts.20
The primary aim of this systematic review will be to 
explore, synthesise and critically evaluate the strength 
and quality of all available evidence on the risk factors 
associated with the development of mental illness (CMDs 
and SMIs) in adults with atopic eczema or psoriasis. If 
possible, we will also compare and contrast the risk factors 
associated with the development of mental illness in 
adults with atopic eczema to the risk factors in psoriasis. 
In the context of this systematic review, we will use the 
term ‘risk factor’ to refer to variables associated with an 
increased risk of mental illness in individuals with atopic 
eczema or psoriasis.
METHODS
This study protocol adheres to the Preferred Reporting 
Items for Systematic Review and Meta- Analysis Protocols 
(PRISMA- P).21
Patient and public involvement
Patients and/or the public were not involved in this 
systematic review protocol.
Eligibility criteria
We will screen studies for potential inclusion in our review 
according to the eligibility criteria presented in table 1.
Information sources
We will search the following databases for relevant articles 
from inception to March 2020: Medline, Embase, Global 
Health, Scopus, the Cochrane Library (which includes 
Cochrane Reviews, Cochrane Protocols, Trials, Editorials, 
Special Collections, Clinical Answers and Other Reviews), 
Table 1 Eligibility criteria
  Inclusion criteria Exclusion criteria
Study design and 
characteristics
All RCTs, cohort, case–control and cross- 
sectional studies where an effect estimate 
(ie, ratio or difference measures) of the risk 
factors for mental illness in adults with atopic 
eczema or psoriasis is reported.
Studies in any language and from any 
geographical setting will be considered.
Ecological studies, case series studies, case reports and 
systematic reviews (however, relevant summary reviews will 
be flagged and reference lists searched for eligible studies).
Studies where correlates (without a measure of effect) have 
been calculated to estimate the association between a risk 
factor and mental illness in adults with atopic eczema or 
psoriasis.
Conference proceedings, letters, editorials, opinion articles 
and reports (however, relevant conference proceedings/
letters will be flagged to try and identify full text).
Participants Human participants aged 18 and over with 
atopic eczema or psoriasis.
Studies including both adults and children 
where data for adults is reported separately.
Studies conducted in children or adolescents only.
Animal or cell studies.
Exposure Risk factors for mental illness (CMD or SMI).   
Comparators Studies must compare adults with atopic 
eczema or psoriasis with the risk factors of 
interest with adults with atopic eczema or 
psoriasis without the risk factors of interest.
  
Outcomes Study outcomes must be a CMD or SMI, 
either clinically diagnosed or self- reported 
with or without validated tools.
  
CMD, common mental disorder; RCT, randomised controlled trial; SMI, severe mental illness.
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Web of Science (which includes the Science Citation Index 
Expanded, the Social Sciences Citation Index, the Arts 
& Humanities Citation Index, the Conference Proceed-
ings Citation Index- Science, the Conference Proceedings 
Citation Index—Social Science & Humanities and the 
Emerging Sources Citation Index), Base, PsycInfo and 
the Global Resource of Eczema Trials. Both Medline and 
Embase capture a large amount of published literature—
Medline indexes more than 5200 journals, and Embase 
indexes almost 8500 journals22 23—while the other data-
bases are likely to contain appropriate papers for this 
review. To ensure that all relevant literature is included in 
the review, we will also search for grey literature in Open 
Grey, the New York Academy of Medicine Grey Liter-
ature Report and PsycExtra. Finally, we will search the 
five largest clinical trial registries— ClinicalTrials. gov, the 
EU Clinical Trials Register, the Japan Primary Registries 
Network, International standard Randomised Controlled 
Trial Number (ISRCTN) and the Australian New Zealand 
Clinical Trials Registry—to identify relevant trials.24
Search strategy
We will search medical subject headings and free text (in 
titles, abstracts and keywords) for synonyms relating to 
three key concepts: (1) ‘risk factors’, (2) ‘atopic eczema 
or psoriasis’ and (3) ‘mental illness’ (table 2). We will 
combine the three key concepts in the search strategy 
using the Boolean logic operator ‘AND’. We have devel-
oped and piloted an initial search strategy in the Medline 
database that has been peer reviewed by a librarian (online 
supplemental table 1), and we will adapt it appropriately 
for other databases. We will also manually scrutinise the 
reference lists and bibliographies of relevant systematic 
reviews to identify additional papers for inclusion. Finally, 
we will use citation searching on large summary papers to 
identify any further relevant publications.
Study records
Data management
A single reviewer (EA) will import all results returned 
from the electronic database searches into the reference 
management tool EndNote V.X9 (Clarivate Analytics, 
V.9.2/2019). After identifying and removing duplicate 
records, we will import the search results into Rayyan (a 
web application for systematic reviews),25 where the inte-
grated deduplication function will be used to identify any 
previously missed duplicates.
Study selection
Two reviewers (EA and YS) will independently screen the 
titles and abstracts of the search results for potentially 
relevant studies. Both reviewers will then screen the full 
text of all potentially relevant studies for inclusion using 
the eligibility criteria. Any disagreements during this 
process will be discussed by EA and YS, with consultation 
from a third reviewer (KM) if necessary. We will record 
and report in a flowchart the reasons for study rejection 
following full text screening.
Data extraction
We will develop a standardised data extraction form 
(to extract information described below), which will be 
piloted by two reviewers (EA and YS) who will extract 
data from the larger of either 10% or five of the eligible 
studies. Any disagreements between the two reviewers will 
be discussed, with a third reviewer (KM) available to arbi-
trate if required, and changes made to the data extraction 
form if necessary. A single reviewer (EA) will complete 
the extraction of data for the remaining studies. We will 
use a modified version of the Population, Intervention, 
Comparator(s), Outcome(s) and Study Design (PICOS) 
framework to summarise data for extraction.26 However, 
due to the inclusion of observational studies in our review, 
we will replace the term ‘intervention’ with ‘exposure’, 
and ‘study design’ will be replaced by ‘study character-
istics’. We will extract information for each component 
of the PICOS framework, in addition to study results for 
each study included in the review (table 3).
Exposures
Our exposures of interest will be risk factors for mental 
illness in people with atopic eczema or psoriasis. We will 
consider any variable that authors of included papers 
have conducted analyses to assess whether they are asso-
ciated with mental illness in people with atopic eczema 
or psoriasis as potential risk factors. These may include 
sociodemographic factors (eg, sex, ethnicity and depri-
vation), lifestyle factors (eg, level of physical activity, diet 
and alcohol consumption) or environmental factors.
Outcomes
Our primary outcome of interest will be mental illness 
in individuals with atopic eczema or psoriasis. Mental 
Table 2 Keywords included in the search strategy for all 
databases
Search term Keywords
Risk factor terms risk OR risk factor* OR protective 
factor OR predict* OR correlat* 
OR associat* OR aetiol* OR etiol* 
OR relationship OR mediat* OR 
mechanism* OR caus* OR path*
Atopic eczema or 
psoriasis terms
atopic dermatitis OR eczema OR 
atopy OR psoriasis OR psoria* OR 
(pustulo* AND palmopl* OR palmari* 
OR palmar)
Mental illness terms mental health OR mental* ill* OR 
mental disorder* OR psychiatr* ill* 
OR psychiatr* disorder OR psychiatr* 
disease* OR psychological* ill* 
OR psychological* disorder* OR 
psychological* disease* OR affective* 
OR anxi* OR depress* OR phobi* OR 
panic OR bipolar* OR schizophrenia 
OR schizo* OR delusion* OR 
psychotic* OR psychos#s OR 
psychological* distress
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illness will be grouped into two broad categories (CMD 
or SMI); unless there are sufficient studies looking at 
specific mental illnesses (eg, depression), then we will 
also explore by specific mental illness subgroup. We will 
include studies regardless of how they capture mental 
illness outcomes (ie, we will include clinical diagnoses or 
self- reported mental illness established with or without 
validated tools).
Risk of bias assessment for individual studies
Two reviewers (EA and YS) will independently assess the 
risk of bias for the larger of 10%, or five, of the included 
studies. Any disagreements will be discussed so that a 
consensus can be reached. A third reviewer (KM) will be 
available to arbitrate if required. A single reviewer (EA) 
will then assess risk of bias for the remaining studies. We 
will use the Quality in Prognosis Studies (QUIPS) tool 
to assess the risk of bias of included studies.27 QUIPS 
assesses and evaluates the risk of bias in six different 
domains: (1) study participation, (2) study attrition, (3) 
prognostic factor measurement, (4) outcome measure-
ment, (5) study confounding and (6) statistical analysis 
and reporting.27 For each study included, we will assess 
and categorise the risk of bias for each domain into one 
of three qualitative categories (low, moderate or high risk 
of bias) using the prompting items provided within the 
tool. We will produce separate risk of bias tables for obser-
vational studies and randomised controlled trials (RCTs) 
along with justifications for the decisions made.
Data synthesis and meta-bias(es)
We will synthesise our results narratively. We will describe 
and tabulate the results of the studies included in the 
review according to the study design (RCT, cohort, case–
control or cross- sectional studies), skin disease type (either 
atopic eczema or psoriasis), risk factor under investiga-
tion and outcome measure (either CMD or SMI). We will 
describe and tabulate the results of the RCTs separately 
from the results of other studies included in the review. If 
possible, we will also identify risk factors that are common 
and distinct between atopic eczema and psoriasis. If at 
least two studies are sufficiently homogeneous (in terms 
of study design, study population, risk factor assessed 
and outcome), we will consider a meta- analysis to pool 
the effect estimates. We will use the I2 statistic to quan-
tify levels of statistical heterogeneity (I2 of 0%–40% may 
indicate negligible heterogeneity, 30%–60% may indicate 
moderate heterogeneity, 50%–90% may indicate substan-
tial heterogeneity and 75%–100% may indicate consid-
erable heterogeneity).24 If possible, we will also consider 
meta- regression to investigate whether study characteris-
tics (eg, study design, risk of bias, study outcome and skin 
disease) or the demographics of the study population 
(eg, age and sex) are associated with the magnitude of 
effects and can explain any observed statistical heteroge-
neity. We will assess the risk of publication bias for the 
studies included in the review using funnel plots. We will 
use STATA V.16.0 to perform all statistical analysis.
Confidence in cumulative evidence
We will use the Grading of Recommendations, Assess-
ment, Development and Evaluation (GRADE) frame-
work to evaluate and summarise the quality of cumulative 
evidence for each broad outcome (CMD or SMI) and 
risk factor pair.28 If more than one study are identified 
for a specific subtype of a CMD or SMI (such as depres-
sion or schizophrenia) and a specific risk factor, we will 
use GRADE to summarise the quality of evidence for that 
subtype. We will categorise the strength of evidence into 
four qualitative categories: ‘high’, ‘moderate’, ‘low’ or 
‘very low’. The quality of evidence for included studies 
will be upgraded if there is a large magnitude of effect or 
a dose- response gradient.28 The quality of evidence will 
be rated down if there is a high risk of bias, imprecision 
in the study estimate, a high probability of publication 
bias or inconsistent results.28 We will present the judge-
ments made during this process in a ‘Summary of Find-
ings’ table.
Ethics and dissemination
As this study is a systematic review that does not involve 
human participation, we do not require ethical approval. 
We will disseminate the results of this review by publishing 
Table 3 Items that will be collected using the data 
extraction form
Parameter Information for extraction
Population Participant inclusion and exclusion criteria
Demographic characteristics (age, sex and 
ethnicity distributions)
Sample size
Exposure Definition and identification of individuals 
with the risk factor(s) of interest
Number of individuals with the risk factor(s) 
of interest
Comparator Definition and identification of individuals 
without the risk factor(s) of interest
Number of individuals without the risk 
factor(s) of interest
Outcome Definition and identification of mental 
illness outcome(s)
Number of individuals in exposed and 
comparison group with the outcome
Study 
characteristics
Bibliographic information (authors, journal, 





Methods of participant recruitment
Aims and objectives
Study results Unadjusted and fully adjusted effect 
estimates for the association between risk 
factors and mental illness
Confounders measured and adjusted for 
analysis
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in an open access, peer- reviewed journal and presenting 
at conferences. We will document any important amend-
ments and protocol deviations, along with justifications, 
and publish them as an appendix in the final review.
Author affiliations
1Department of Non- Communicable Disease Epidemiology, London School of 
Hygiene & Tropical Medicine, London, UK
2Siaal Research Center for Family Medicine and Primary Care, Faculty of Health 
Sciences, Ben- Gurion University of the Negev, Beer Sheva, Israel
3Department of Quality Measurements and Research, Clalit Health Services, Tel Aviv, 
Israel
4Division of Psychiatry, University College London, London, UK
5Department of Psychological Medicine, Institute of Psychiatry, Psychology, and 
Neuroscience, King's College London, London, UK
6St John's Institute of Dermatology, Guys and St Thomas' Foundation Trust and 
King's College London, London, UK
7Health Data Research UK, London, UK
Contributors EA, SL and KM had the original idea for the review. All authors (EA, 
YS, JH, RM, AM, LR, LS, CHS, SL and KM) were involved in the design of the study. 
EA wrote the first draft of the protocol. All authors (EA, YS, JH, RM, AM, LR, LS, CHS, 
SL and KM) contributed to further drafts and approved the final manuscript. Kate 
Perris peer reviewed the search strategy.
Funding EA was funded by a British Skin Foundation (BSF) PhD studentship 
(Reference: 024/S/18). SL was funded by a Wellcome Trust Senior Clinical 
Fellowship in Science (Reference: 205039/Z/16/Z).
Competing interests None declared.
Patient consent for publication Not required.
Provenance and peer review Not commissioned; internally peer reviewed.
Supplemental material This content has been supplied by the author(s). It has 
not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been 
peer- reviewed. Any opinions or recommendations discussed are solely those 
of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and 
responsibility arising from any reliance placed on the content. Where the content 
includes any translated material, BMJ does not warrant the accuracy and reliability 
of the translations (including but not limited to local regulations, clinical guidelines, 
terminology, drug names and drug dosages), and is not responsible for any error 
and/or omissions arising from translation and adaptation or otherwise.
Open access This is an open access article distributed in accordance with the 
Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits 
others to copy, redistribute, remix, transform and build upon this work for any 
purpose, provided the original work is properly cited, a link to the licence is given, 
and indication of whether changes were made. See: https:// creativecommons. org/ 
licenses/ by/ 4. 0/.
ORCID iDs
Elizabeth I Adesanya http:// orcid. org/ 0000- 0002- 8912- 7520
Rohini Mathur http:// orcid. org/ 0000- 0002- 3817- 8790
Amy R Mulick http:// orcid. org/ 0000- 0002- 4009- 2080
Sinéad M Langan http:// orcid. org/ 0000- 0002- 7022- 7441
Kathryn E Mansfield http:// orcid. org/ 0000- 0002- 2551- 410X
REFERENCES
 1 Parisi R, Symmons DPM, Griffiths CEM, et al. Global epidemiology of 
psoriasis: a systematic review of incidence and prevalence. J Invest 
Dermatol 2013;133:377–85.
 2 Barbarot S, Auziere S, Gadkari A, et al. Epidemiology of atopic 
dermatitis in adults: results from an international survey. Allergy 
2018;73:1284–93.
 3 GBD 2017 Disease and Injury Incidence and Prevalence 
Collaborators. Global, regional, and national incidence, prevalence, 
and years lived with disability for 354 diseases and injuries for 195 
countries and territories, 1990-2017: a systematic analysis for the 
global burden of disease study 2017. Lancet 2018;392:1789–858.
 4 NHS Digital. Adult psychiatric morbidity survey: survey of mental 
health and wellbeing, England, 2014. Available: https:// digital. nhs. 
uk/ data- and- information/ publications/ statistical/ adult- psychiatric- 
morbidity- survey/ adult- psychiatric- morbidity- survey- survey- of- 
mental- health- and- wellbeing- england- 2014# key- facts [Accessed 21 
Jan 2020].
 5 Chesney E, Goodwin GM, Fazel S. Risks of all- cause and suicide 
mortality in mental disorders: a meta- review. World Psychiatry 
2014;13:153–60.
 6 Eckert L, Gupta S, Amand C, et al. Impact of atopic dermatitis on 
health- related quality of life and productivity in adults in the United 
States: an analysis using the National health and wellness survey.  
J Am Acad Dermatol 2017;77:274–9.
 7 Klokk M, Gotestam KG, Mykletun A. Factors accounting for the 
association between anxiety and depression, and eczema: the 
Hordaland health study (husk). BMC Dermatol 2010;10:3.
 8 Schmitt J, Romanos M, Pfennig A, et al. Psychiatric comorbidity in 
adult eczema. Br J Dermatol 2009;161:878–83.
 9 Ferreira BR, Pio- Abreu JL, Reis JP, et al. Analysis of the prevalence 
of mental disorders in psoriasis: the relevance of psychiatric 
assessment in dermatology. Psychiatr Danub 2017;29:401–6.
 10 Kurd SK, Troxel AB, Crits- Christoph P. The risk of depression, 
anxiety, and suicidality in patients with psoriasis: a population- based 
cohort study. Arch Dermatol 2010;146:891–5.
 11 HP T, CL Y, CCE L. Prevalence of schizophrenia in patients with 
psoriasis: a nationwide study. Dermatologica Sin 2017;35:1–6.
 12 Schonmann Y, Mansfield KE, Hayes JF, et al. Atopic eczema in 
adulthood and risk of depression and anxiety: a population- based 
cohort study. J Allergy Clin Immunol Pract 2020;8:248–57.
 13 Drucker AM, Thiruchelvam D, Redelmeier DA. Eczema and 
subsequent suicide: a matched case- control study. BMJ Open 
2018;8:e023776.
 14 Sandhu JK, Wu KK, Bui T- L, et al. Association between atopic 
dermatitis and suicidality: a systematic review and meta- analysis. 
JAMA Dermatol 2019;155:178–87.
 15 Bao Q, Chen L, Lu Z, et al. Association between eczema and risk 
of depression: a systematic review and meta- analysis of 188,495 
participants. J Affect Disord 2018;238:458–64.
 16 Rønnstad ATM, Halling- Overgaard A- S, Hamann CR, et al. 
Association of atopic dermatitis with depression, anxiety, and 
suicidal ideation in children and adults: a systematic review and 
meta- analysis. J Am Acad Dermatol 2018;79:448–56.
 17 Dowlatshahi EA, Wakkee M, Arends LR, et al. The prevalence and 
odds of depressive symptoms and clinical depression in psoriasis 
patients: a systematic review and meta- analysis. J Invest Dermatol 
2014;134:1542–51.
 18 Ferreira BIRC, Abreu JLPDC, Reis JPGD, et al. Psoriasis and 
associated psychiatric disorders: a systematic review on 
etiopathogenesis and clinical correlation. J Clin Aesthet Dermatol 
2016;9:36–43 https://www. ncbi. nlm. nih. gov/ pmc/ articles/ 
PMC4928455/
 19 Patel KR, Immaneni S, Singam V, et al. Association between atopic 
dermatitis, depression, and suicidal ideation: a systematic review 
and meta- analysis. J Am Acad Dermatol 2019;80:402–10.
 20 Xie Q- W, Dai X, Tang X, et al. Risk of mental disorders in children and 
adolescents with atopic dermatitis: a systematic review and meta- 
analysis. Front Psychol 2019;10:10.
 21 Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for 
systematic review and meta- analysis protocols (PRISMA- P) 2015 
statement. Syst Rev 2015;4:1.
 22 U.S National Library of Medicine. Fact sheet: Medline. Available: 
https://www. nlm. nih. gov/ lstrc/ jsel. html [Accessed 27 Jan 2020].
 23 Elsevier. EMBASE: coverage and content. Available: https://www. 
elsevier. com/ solutions/ embase- biomedical- research/ embase- 
coverage- and- content [Accessed 27 Jan 2020].
 24 Huser V, Cimino JJ. Evaluating adherence to the International 
Committee of medical Journal editors' policy of mandatory, timely 
clinical trial registration. J Am Med Inform Assoc 2013;20:e169–74.
 25 Ouzzani M, Hammady H, Fedorowicz Z, et al. Rayyan- a web and 
mobile APP for systematic reviews. Syst Rev 2016;5:210.
 26 Higgins J, Green S. Cochrane Handbook for systematic reviews of 
interventions: version 5.1.0 (updated March 2011), 2011. Available: 
www. handbook- 5- 1. cochrane. org [Accessed 21 Jan 2020].
 27 Hayden JA, van der Windt DA, Cartwright JL, et al. Assessing bias in 
studies of prognostic factors. Ann Intern Med 2013;158:280–6.
 28 Guyatt GH, Oxman AD, Vist GE, et al. Grade: an emerging consensus 
on rating quality of evidence and strength of recommendations. BMJ 
2008;336:924–6.









pen: first published as 10.1136/bm
jopen-2020-038324 on 28 D
ecem
ber 2020. D
ow
nloaded from
 
